First Patient Enrolled in HIV Combination Maintenance Therapy Study
July 29, 2022
TMB-a21 is a Phase 1b/2a study involving HIV-1 infected patients who are virally suppressed. The investigational products, TMB-365 and TMB-380, are monoclonal antibodies administered together via intravenous infusion. The study is designed to evaluate the safety, pharmacokinetics, and efficacy of this experimental combination at different doses and dosing intervals.
Westat’s Senior Project Director, Susan Denton, commented, “Westat is honored to work with TaiMed on this groundbreaking HIV research. We’ve worked with TaiMed for more than ten years and continue to focus our efforts on improving the health of people infected with HIV-1.”
Westat CLS—Showcasing CRO Services to Commercial Clients
What Pneumonia Vaccine Prompts the Best Immunity Response in Infants Whose Mothers Have HIV?
First Next-Generation Freeze-Dried Plasma (FDP) Product Found to Be as Safe and Potent as Fresh Frozen Plasma (FFP)